Adverse bone effects of medications used to treat non-skeletal disorders (Q48332195)

10 February 2018

title

Adverse bone effects of medications used to treat non-skeletal disorders (English)

1 reference

10 February 2018

author

Nelson B Watts

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28752332 AND SRC:MED&resulttype=core&format=json

7 June 2020

author name string

N B Watts

series ordinal

1

1 reference

10 February 2018

language of work or name

English

0 references

publication date

27 July 2017

1 reference

10 February 2018

Osteoporosis International

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28752332 AND SRC:MED&resulttype=core&format=json

7 June 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28752332 AND SRC:MED&resulttype=core&format=json

7 June 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28752332 AND SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

2741-2746

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28752332 AND SRC:MED&resulttype=core&format=json

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

7 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Management of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Clinical practice. Glucocorticoid-induced bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Glucocorticoid-Induced Osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Fracture risk in patients treated with loop diuretics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Hyponatremia-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Hyponatremia and fractures: should hyponatremia be further studied as a potential biochemical risk factor to be included in FRAX algorithms?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Effects of three years of low-dose thiazides on mineral metabolism in healthy elderly persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Thiazide diuretic agents and the incidence of hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Diuretic Use and Risk of Vertebral Fracture in Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Bone density recovery after depot medroxyprogesterone acetate injectable contraception use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Luteinizing hormone-releasing hormone and its analogues: a review of biological properties and clinical uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Overview of elagolix for the treatment of endometriosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Basic understanding of gonadotropin-releasing hormone-agonist triggering

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

The updated Cochrane review 2014 on GnRH agonist trigger: an indispensable piece of information for the clinician.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

The effect of gonadotrophin-releasing hormone agonist treatment over 3 years on bone mineral density and body composition in girls with central precocious puberty.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Bone mineral density and body composition in girls with idiopathic central precocious puberty before and after treatment with a gonadotropin-releasing hormone agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Advances in pharmacotherapy for treating endometriosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Safety of medical treatments for endometriosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Fibroid growth and medical options for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Adenomyosis: a systematic review of medical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Low-dose add-back therapy during postoperative GnRH agonist treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Antiresorptive therapy in the management of cancer treatment-induced bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Bone health management in men undergoing ADT: examining enablers and barriers to care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Bone health in cancer patients: ESMO Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Diabetes mellitus and risk of hip fractures: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Risk factors for hip fracture in men. Hip Fracture Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Proton-pump inhibitors and risk of fractures: an update meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Use of proton pump inhibitors and mortality after hip fracture in a nationwide study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

A review of the effect of anticonvulsant medications on bone mineral density and fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Bone disease during chronic antiepileptic drug therapy: general versus specific risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Best practice guidelines for the management of women with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Possible methods for the prevention of bone loss in persons with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Serotonin-norepinephrine reuptake inhibitor and selective serotonin reuptake inhibitor use and risk of fractures: a new-user cohort study among US adults aged 50 years and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

SSRI use and risk of fractures among perimenopausal women without mental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Use of selective serotonin reuptake inhibitors and bone mass in adolescents: An NHANES study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

The emerging role of serotonin (5-hydroxytryptamine) in the skeleton and its mediation of the skeletal effects of low-density lipoprotein receptor-related protein 5 (LRP5).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Use of antipsychotics increases the risk of fracture: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Vitamin K antagonists' use and fracture risk: results from a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Association Between Dabigatran vs Warfarin and Risk of Osteoporotic Fractures Among Patients With Nonvalvular Atrial Fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Bone mineral density in women aged 25–35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-017-4171-4

Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin

21 January 2018

1 reference

12 December 2020

Loop diuretic use and fracture in postmenopausal women: findings from the Women's Health Initiative

1 reference

12 December 2020

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

1 reference

12 December 2020

Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

1 reference

12 December 2020

Effects of third-generation aromatase inhibitors on bone

1 reference

12 December 2020

Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer

1 reference

12 December 2020

Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture

1 reference

12 December 2020

Fracture incidence after 3 years of aromatase inhibitor therapy

1 reference

12 December 2020

Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study

1 reference

12 December 2020

The impact of depot medroxyprogesterone acetate on fracture risk: a case-control study from the UK.

1 reference

12 December 2020

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

1 reference

12 December 2020

Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up

1 reference

12 December 2020

Prolonged heparin therapy in pregnancy causes bone demineralization

1 reference

12 December 2020

Association of Proton Pump Inhibitor Use with Recurrent Falls and Risk of Fractures in Older Women: A Study of Medication Use in Older Fallers

1 reference

12 December 2020

Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study

1 reference

12 December 2020

Postpartum osteoporosis and vertebral fractures in two patients treated with enoxaparin during pregnancy

1 reference

12 December 2020

Glucocorticoid-induced Osteoporosis

1 reference

12 December 2020

A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry

1 reference

12 December 2020

10.1007/S00198-017-4171-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28752332 AND SRC:MED&resulttype=core&format=json

7 June 2020

1 reference